Home » Topics » BioWorld Science

BioWorld Science
RSS

FDA lifts partial clinical hold on phase Ib study of RVU-120 in AML and MDS

July 15, 2021

Dosing commences in phase II study of STP-705 for keloid scar prevention

July 15, 2021

Escient reports phase I data on EP-547 for pruritus associated with cholestasis and uremia

July 15, 2021

Antibiotics double as antitumor kinase inhibitors

July 15, 2021

Discovery of novel siderophore-monobactam conjugates against P. Aeruginosa

July 15, 2021

Adial reports preclinical data with adenosine analogues for pain

July 15, 2021

CIHR grant supports Arch's evaluation of LSALT in chronic kidney and lung diseases

July 15, 2021

Enrollment begins in phase I study of BI-1810631 in advanced solid tumors

July 15, 2021

DDX21 has prognostic impact in adrenocortical carcinoma

July 15, 2021

Revalesio initiates phase II study of RNS-60 in acute ischemic stroke

July 15, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 6, 2026.
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...
CROI 2026 highlights depression and cognitive vulnerability in HIV
BioWorld
The effects of aging pose an additional challenge for people with HIV due to the neurological and psychological consequences that persist despite antiretroviral...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
Slate Medicines launches with focus on headache disorders
BioWorld Science
Slate Medicines Inc. has launched with $130 million in series A financing and a focus on advancing next-generation therapeutics for migraine and other headache...